Institute of Human Virology (IHV) is the first Institute at University of Maryland School of Medicine
(355)
The Institute of Human Virology (IHV) is the first center in the United States - perhaps the world - to combine the disciplines of basic science, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably HIV, the cause of AIDS. Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in the field of human virology. The Institute, with its various laboratory and patient care facilities, is uniquely housed in a 100,000-square-foot building located in the center of Baltimore and our nation’s HIV/AIDS pandemic. IHV creates an environment where multidisciplinary research, education and clinical programs work closely together to expedite the scientific understanding of HIV/AIDS pathogenesis and to develop therapeutic interventions to make AIDS and virally-caused cancers manageable, if not curable, diseases. A particular focus of IHV includes learning how to utilize the body's natural chemistry for its own therapeutic potential and pursuing biologically-based treatment approaches that are less toxic to the body and, often, less costly to the patient and public. IHV also pursues the development of effective therapeutic and preventative vaccines, science's greatest hope in putting an end to the AIDS pandemic. IHV's more than 300 employees include 73 faculty whose research efforts are focused in the area of chronic human viral infection and disease. At present, more than 75 percent of the Institute's clinical and research effort is targeted at HIV infection, but also includes the Hepatitis C virus, herpes viruses and cancer research.
12/05/2025
As we end the first week of , we’re excited to share a new episode of the podcast!
This week, we talk with The Thrive Program Baltimore’s Eric Anderson and Robyn Palmerio about the power of patient-centered care. Their passion and dedication remind us what World AIDS Awareness Month is all about: compassion, connection, and community.
🎧 Listen to the episode and join us in honoring this month of awareness and action.
>>LINK IN COMMENTS
12/02/2025
We closed out by celebrating Manhattan E. Charurat, PhD, MHS, who was investured as the Homer and Martha Gudelsky Distinguished Professor in Medicine at the University of Maryland School of Medicine.
Speakers, including Institute of Human Virology Co-Founder William Blattner, MD, highlighted his research on mother-to-child HIV transmission, mobile testing innovations, and the more than
$200 million in global health partnerships he has brought to UMSOM.
12/01/2025
IHV is proud to share this IAS video on the importance of person-centred care in the global HIV response. We’re especially pleased to see Ciheb Global 's Dr. Marie-Claude Lavoie featured alongside community advocates highlighting why putting people first is essential to ending the HIV epidemic.
👥 Watch the video to hear their insights.
The IAS Person-Centred Care (PCC) programme improves health services by prioritizing the integration of health concerns and the responsiveness of healthcare ...
12/01/2025
Today on World AIDS Day, we join the global call to “Overcome Disruption and Transform the AIDS Response.” At IHV, we’re proud to support research, innovation, and community partnerships that move us closer to ending HIV for good.
11/24/2025
🚨 New Research Published! 🚨
Researchers from IHV have identified a key mechanism that may explain why HIV continues to persist in the body — even with highly effective antiretroviral therapy.
Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a specific type of immune cell may contribute to the persistence of HIV infections. The finding offers new insight into why the virus remains difficult to cure even with effe...
11/18/2025
We’re proud of the impactful, community-driven work The Jacques Initiative continues in Baltimore. Their commitment strengthens public health and advances meaningful, accessible education and care.
11/14/2025
😓 Missed the 18th Annual Greenebaum Lecture? We’ve got you covered! ☺️
The full event is now available to watch online. Hear insights from Dr. Moupali Das and Dr. Anu Osinusi of Gilead Sciences as they discuss advances in HIV prevention and innovation across virology.
Nov. 11, 2025| Moupall Dass, MD, MPH "Lenacapavir for HIV Prevention:The PURPOSE Program” & Anu Osinusi, MD, MPH “Viruses Don’t Wait: Innovation Across Viro...
11/13/2025
What an inspiring 18th Annual Greenebaum Lecture at the Institute of Human Virology, University of Maryland School of Medicine!
This year’s speakers, Dr. Moupali Das and Dr. Anu Osinusi of Gilead Sciences, shared groundbreaking insights on and viral innovation.
🧬 Dr. Das discussed “ for HIV Prevention: The PURPOSE Program,” highlighting how long-acting therapies are transforming prevention efforts.
🦠 Dr. Osinusi followed with “Viruses Don’t Wait: Innovation Across Virology,” exploring the cutting edge of , respiratory, and emerging virus research.
A sincere thank-you to our speakers, attendees, and community for advancing the conversation in global health and virology.
11/12/2025
🎙️ We sit down with Kerry Hawk Lessard of Native American LifeLines of Baltimore for an enlightening conversation about Baltimore’s Indigenous history and the vibrant Urban Indigenous community shaping its future. 🌿
🔗 in comments!
11/06/2025
From cultural preservation to health equity, Kerry Lessard shares how identity, tradition, and wellness intersect in urban spaces — and how Baltimore’s Indigenous voices continue to shape the city’s story.
👏 Congrats to Michael Wu, PhD candidate Institute of Human Virology for presenting his poster “A novel LNP/mRNA-based STING immunotherapy approach for chronic HBV infection” at the HBV 2025 Meeting in Berlin 🇩🇪 ! 🌍
“Each discovery brings us closer to transforming chronic HBV from a lifelong burden into a curable condition,” said Wu.
Be the first to know and let us send you an email when Institute of Human Virology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
The Institute of Human Virology (IHV) is the first center in the United States - perhaps the world - to combine the disciplines of basic science, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably HIV, the cause of AIDS.
Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in the field of human virology. IHV was co-founded by Robert Gallo, MD, director of the of the IHV, William Blattner, MD, retired since 2016 and formerly associate director of the IHV and director of IHV’s Division of Epidemiology and Prevention and Robert Redfield, MD, resigned in March 2018 to become director of the U.S. Centers for Disease Control and Prevention (CDC) and formerly associate director of the IHV and director of IHV’s Division of Clinical Care and Research. In addition to the two Divisions mentioned, IHV is also comprised of a Basic Science Division, Vaccine Research Division, Immunotherapy Division, Center for International Health, Education and Biosecurity (CIHEB) and four Scientific Core Facilities.
The Institute, with its various laboratory and patient care facilities, is uniquely housed in a 250,000-square-foot building located in the center of Baltimore and our nation’s HIV/AIDS pandemic. IHV creates an environment where multidisciplinary research, education, and clinical programs work closely together to expedite the scientific understanding of HIV/AIDS pathogenesis and to develop therapeutic interventions to make AIDS and virally-caused cancers manageable, if not curable, diseases.
A particular focus of IHV includes learning how to utilize the body's natural chemistry for its own therapeutic potential and pursuing biologically-based treatment approaches that are less toxic to the body and, often, less costly to the patient and public. IHV also pursues the development of effective therapeutic and preventative vaccines, science's greatest hope in putting an end to the AIDS pandemic.L
IHV's more than 300 employees include more than 80 faculty whose research efforts are focused in the area of chronic human viral infection and disease. At present, more than 75 percent of the Institute's clinical and research effort is targeted at HIV infection, but also includes hepatitis C virus, human T cell leukemia viruses 1 and 2, human papillomavirus, herpes viruses and cancer research. IHV’s patient base has grown from just 200 patients to approximately 5,000 in Baltimore and more than 2,000,000 in African and Caribbean nations.
